Vitamin B12 (cobalamin) sits at the junction of one-carbon metabolism, where it serves as the cofactor for methionine synthase and thereby governs the supply of the universal methyl donor S-adenosylmethionine. This article reviews, for research audiences only, how experimental models describe cobalamin's influence on DNA, RNA and protein methylation and on genome stability.

Where B12 sits in one-carbon and methylation networks

One-carbon metabolism is the network of interlocking folate and methionine cycles that shuttles single-carbon units for nucleotide synthesis and for methylation reactions. Vitamin B12 occupies a defined node within it. In its methylcobalamin form, cobalamin is the cofactor for cytosolic methionine synthase (MTR), the enzyme that transfers a methyl group from 5-methyltetrahydrofolate (5-methyl-THF) to homocysteine, regenerating methionine.³ Methionine is then adenylated by methionine adenosyltransferase to form S-adenosylmethionine (SAM), the methyl donor consumed by the large family of SAM-dependent methyltransferases.

Studies using neuronal cell models with engineered reductions in cobalamin availability describe how this cofactor role links directly to downstream epigenetic machinery: reduced cellular cobalamin alters proliferation, differentiation and methylation-sensitive signalling.³ The key steps that research models trace are as follows.

• Methionine synthase (B12-dependent): transfers the methyl group of 5-methyl-THF to homocysteine, yielding methionine and regenerating tetrahydrofolate.³
• Methionine adenosyltransferase: converts methionine to SAM, supplying methyl groups for reactions throughout the cell.
• SAM-dependent methyltransferases: catalyse DNA, RNA, histone and phospholipid methylation, releasing S-adenosylhomocysteine (SAH) as a by-product.

Because methionine synthase is the only cobalamin-dependent enzyme in the cytosol, it forms a single, tractable point at which changes in cobalamin status propagate into the whole methylation economy of the cell. That structural fact is why cobalamin has become a recurring probe in methylation research.

The methyl-folate trap and the SAM/SAH ratio

The classical consequence of limited cobalamin is the "methyl-folate trap." When methionine synthase activity falls, 5-methyl-THF cannot be demethylated and accumulates, while other reduced folate forms needed for nucleotide synthesis are depleted. Homocysteine, unable to be remethylated efficiently, rises.¹ In parallel, reduced SAM synthesis and rising SAH lower the SAM/SAH ratio, a commonly used surrogate for cellular methylation capacity because SAH is a product-inhibitor of most methyltransferases.

The transcobalamin receptor (TCblR/CD320) knockout mouse offers a clean demonstration. In this model, ablation of the receptor produces severe central-nervous-system cobalamin depletion, with elevated methylmalonic acid, homocysteine and cystathionine, and a significantly decreased SAM/SAH ratio in the brain.² The metabolic signature matches what the folate-trap hypothesis predicts, and it isolates the effect of restricted cellular cobalamin uptake from dietary confounders.

It is worth stating the limits of the SAM/SAH surrogate. A depressed ratio indicates constrained methylation capacity in aggregate, but individual methyltransferases differ widely in their sensitivity to SAH and in their SAM affinities. Consequently, a fall in the global ratio does not translate uniformly across every methylation target, and research designs increasingly pair the ratio with locus-specific or genome-wide readouts.

DNA methylation across cellular and population models

DNA methylation, principally at cytosine-guanine (CpG) dinucleotides, is the most studied output of cobalamin-dependent methyl supply. In cultured human cells and rodent tissues, reduced cobalamin availability has been associated with global DNA hypomethylation, consistent with a constrained SAM pool.¹³ Work correlating methionine synthase activity with tissue DNA methylation in proliferating intestinal epithelium reinforces the mechanistic link between the enzyme and the methylome.³

At population scale, epigenome-wide association studies test whether B-vitamin status tracks with methylation patterns in accessible tissues such as blood. A meta-analysis of 5,841 individuals reported associations between dietary folate and vitamin B12 intake and genome-wide DNA methylation, identifying differentially methylated positions linked to intake.⁵ A separate study using metabolomic biomarkers of habitual B-vitamin intake likewise surfaced novel differentially methylated positions in the human epigenome.⁸ Related fortification-cohort work on folic acid, the folate partner of cobalamin in the same cycle, has examined placental DNA methylation and illustrates how one-carbon nutrient supply is probed epigenetically.¹⁰

These association findings are informative but correlational: they cannot, on their own, establish that cobalamin drives the observed methylation differences, and effect sizes at individual CpGs are typically small. They are best read as hypothesis-generating signals that motivate controlled cell and animal experiments, rather than as evidence of a causal or clinical effect.

Beyond DNA: SAM, RNA methylation and the epitranscriptome

Because SAM is the shared donor for essentially all cellular methylation, cobalamin's influence is not confined to DNA. RNA modifications, most abundantly N6-methyladenosine (m6A), are installed by SAM-dependent methyltransferases and are therefore, in principle, sensitive to methyl-donor availability. The methyltransferase METTL16 has been shown to sense SAM levels and fine-tune the expression of the SAM-synthesising enzyme in direct response to fluctuations in donor availability, forming a feedback loop that couples the epitranscriptome to one-carbon metabolism.⁹

This mechanistic architecture makes RNA methylation a plausible downstream reporter of cobalamin status, and neuronal cell models with reduced cobalamin describe broader epigenomic deregulation extending to histone and non-DNA targets.³ Direct experimental evidence tying defined cobalamin status to quantified changes in m6A or other RNA marks remains limited, however, and this link should be treated as a research hypothesis rather than an established pathway. It is an active area where cobalamin serves as a tractable input variable for perturbing the methyl-donor pool.

Cobalamin, genome instability and DNA damage

A second, distinct consequence of cobalamin limitation concerns nucleotide synthesis and genome integrity. Because the methyl-folate trap depletes 5,10-methylene-THF, thymidylate synthesis (dUMP to dTMP) slows, favouring uracil misincorporation into DNA. Base-excision repair of that uracil generates transient single-strand nicks; when clustered, these can produce strand breaks and chromosomal damage. Fenech's foundational cell-based work established that low folate and, by extension, low cobalamin correlate with chromosome breakage, uracil misincorporation and micronucleus formation, with genomic instability minimised above defined folate thresholds in culture.¹

A contemporary review synthesises the wider picture, noting that cobalamin contributes to DNA stability both through its methylation and nucleotide-synthesis roles and through reported antioxidant activity that scavenges reactive oxygen species; deficiency in models is associated with intensified oxidative DNA stress and impaired methylation.⁴ The mechanisms researchers typically separate are:

1. The dUMP-to-dTMP bottleneck

Reduced cobalamin limits methylene-THF, slowing dTMP synthesis so that dUMP is misincorporated, seeding strand breaks and replication stress in cellular models.¹

2. DNA-repair burden

Uracil in DNA activates base-excision repair; iterative repair at densely uracil-substituted regions increases single- and double-strand breaks, adding chromosomal stress in cultured cells.¹

3. Oxidative component

Rising homocysteine and altered redox balance are associated with greater reactive-oxygen-species burden in deficiency models, so oxidative lesions compound the replication-linked damage.⁴ This redox dimension is one reason cobalamin studies are sometimes run alongside other metabolic-cofactor reagents such as NAD+ in experimental designs probing cellular energetics and stress.

Inherited cobalamin defects as natural experiments

Human inborn errors of cobalamin metabolism, together with their patient-derived cell lines, function as informative natural experiments because they isolate specific steps of the pathway. The cblC disorder, caused by mutations in MMACHC, impairs intracellular synthesis of both methylcobalamin and adenosylcobalamin, the coenzymes for methionine synthase and methylmalonyl-CoA mutase respectively. The result is combined methylmalonic aciduria and homocystinuria, with reduced methionine, and studies on patient fibroblasts have mapped how individual residue deletions perturb MMACHC function and cobalamin handling.⁶ Such fibroblast models let researchers observe methionine-synthase-dependent effects on the SAM/SAH balance under a defined genetic lesion.

The TCblR/CD320 knockout mouse complements these cell systems at the organismal level. Beyond the metabolic signature already noted, the model exhibits central-nervous-system cobalamin depletion accompanied by behavioural alterations, impaired hippocampal long-term potentiation and reduced brain mass, linking restricted cellular cobalamin uptake to measurable neural phenotypes.⁷ Together, the genetic-defect and receptor-knockout models allow cobalamin's methylation role to be interrogated without the confounders of dietary manipulation.

Study models and functional biomarkers

Selecting a model means matching the question to the level of control required. Cultured human cells permit precise titration of cobalamin and folate and rapid readout of methylation and damage markers, but abstract away systemic physiology. Genetic-defect fibroblasts and receptor-knockout animals restore pathway specificity and organ context at the cost of throughput. Population EWAS trade mechanistic control for statistical power and human relevance.⁵

Interpreting any of these depends on functional biomarkers rather than total serum cobalamin alone. Holotranscobalamin reports the fraction of cobalamin available for cellular uptake, while methylmalonic acid and homocysteine rise when the two cobalamin-dependent enzymes are undersupplied, giving a functional rather than purely quantitative picture.² DNA-integrity endpoints, such as micronucleus counts, strand-break assays and gamma-H2AX foci, are frequently paired with these metabolic markers so that methylation capacity and genome stability are assessed together.¹ Investigators studying mitochondrial and metabolic axes sometimes situate cobalamin work alongside peptide reagents such as MOTS-C when the experimental focus extends to cellular energetics.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.